S
ymptomatic bradycardia is the most common indication for permanent pacemaker implantation, which can result in cerebral hypoperfusion and subsequent syncope. 1, 2 In symptomatic patients with a ventricular pause of more than 3 seconds, the European Society of Cardiology and American Heart Association guidelines recommend pacemaker implantation in these patients to prevent further adverse events, except for patients who were asleep or on medication. [1] [2] [3] [4] However, the current 3-second criterion is an arbitrary clinical observation with a low specificity. 3 duration) did develop syncope that eventually leads to pacemaker implantation. 1, 2, 6, 7 There were no long-term follow-up data regarding patients with intermediate pauses and future cardiovascular events and mortality. Whether these asymptomatic patients with intermediate pauses have a benign clinical course for future cardiovascular events remains unclear. In this study, using the 24-hour Holter monitoring database in a patient population that was followed up for 8 years, we will be able to explore the long-term risk of cardiovascular events and mortality in patients with intermediate pauses.
Pauses at nighttime have been considered to be a physiological rather than pathological response attributed to autonomic regulation and might spare intensive intervention. Therefore, intermediate pauses occurring at daytime or nighttime may have a different impact on cardiovascular risks. Furthermore, the patterns (ie, atrioventricular block [AVB] or sinus arrest) and frequency of these intermediate pauses might also differently contribute to cardiovascular events with respect to their occurring time. We hypothesize that intermediate pauses occurring at daytime is associated with higher cardiovascular risk and mortality rate than those at nighttime.
Methods
This study was approved by the Institutional Review Board at Taipei Veterans General Hospital, Taipei, Taiwan (VGH-IRB Number: 2013-08-002AC#1). Because the patient records/ information was anonymous and de-identified before analysis, there was no need for obtaining patients' informed consent. The data, analytical methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure because this was not part of our original Institutional Review Board approval.
Study Population
This retrospective, observational study was performed by analyzing the "Registry of 24-hour ECG monitoring at Taipei Veterans General Hospital" database. Taipei Veterans General Hospital is a large integrated healthcare delivery system and provides comprehensive medical services to more than 3 million people in Taiwan. The study database included 5903 consecutive patients who were aged >18 years and who underwent clinically indicated 24-hour Holter monitoring between January 1, 2002 and December 31, 2004. Indications for Holter monitoring were palpitation, syncope, suspected arrhythmia, and clinical followup by the physicians' discretion. Clinical variables, including past medical histories, risk factors, comorbidities, and medications, were obtained from the medical records of the primary/ secondary referral hospitals, outpatient visits, emergency visits, the Collaboration Center of Health Information Application (CCHIA), and the Ministry of Health and Welfare in Taiwan. The International Classification of Diseases -Ninth Revision (ICD-9) codes were also used for identifying underlying diseases, including diabetes mellitus, hypertension, coronary artery disease, heart failure, chronic kidney disease, liver disease, myocardial infarction, and valvular heart disease. The New York Heart Association functional classifications of patients were determined from the medical and nursing records.
Clinical diagnoses of interests were confirmed to be valid only if they have been recorded at least twice in outpatient records or once in hospitalization records. Patients were excluded if they have atrial flutter/AF, high-degree AVB, symptomatic bradycardia, or the longest R-R interval is ≥3 seconds by the 12-lead ECG or 24-hour Holter monitoring. Patients were also excluded if they had a pacemaker implanted before this study or had a history of catheter ablation for arrhythmia. After excluding the above-mentioned patients, the final sample size was 5291 patients.
Cardiovascular Outcomes
The primary outcome in this study is mortality. hospitalization), hospitalization for cardiovascular causes, the occurrence of new-onset AF, new-onset heart failure (HF), permanent pacemaker (PPM) implantation, transient ischemic attack (TIA) and ischemic stroke. Patients taking regular medication were regularly followed up at an interval of 1 to 3 months. Those with a new cardiovascular event were followed up every 2 weeks for the first month and at an interval of 1 to 3 months thereafter. Patients who did not take regular medication were followed up annually or at the discretion of the physicians. Medical records retrieved from the Taipei Veterans General Hospital were used for outcome survey as in our previous study. 8 New cardiovascular events, inpatient admissions, and deaths were identified through the ICD diagnostic codes, mention of an end point on the face sheet of the medical record, previous discharge summary, and outpatient clinic reports. Mortality was defined as passing away during hospitalization or discharge under critical condition. Hospitalization was defined as an overnight stay in a hospital ward, excluding emergency department visit. New-onset HF and AF were identified by physician report, echocardiography data, ECG tracing, and mention of the events in the medical record. The observation period was from the date of patient registration until February 28, 2013. Multivariate analysis with the Cox hazards regression model was used to assess the hazard ratio (HR) for mortality (primary outcome) and adverse cardiovascular events (secondary outcome).
Patient Groups and Definition of Pauses
The 24-hour Holter monitoring data were reviewed by electrophysiological experts as in our previous work. 8 were those whose pause occurrence frequency was equal or higher than the median frequency in each group. The rest of the patients in each group constituted the low-frequency patients.
Statistical Analysis
Statistical analyses were performed by SPSS statistical software (version 20.0; SPSS, Inc., Chicago, IL). Patient characteristics are expressed as meanAESD for continuous variables and percentages for categorical variables. Continuous and categorical variables were compared using the Student t test and Pearson's chi-square test with Yates' correction, respectively. An alpha error of less than 5% was considered statistically significant. Kaplan-Meier survival curves with log-rank tests were used to analyze survival data (time to adverse event). A Cox regression hazards model was applied to estimate the HR of the time to adverse events.
Results

Baseline Characteristics
A total of 5291 patients were enrolled in this study: 4859 (91.8%) were in the NOP (control) group, whereas 248 (4.7%), 103 (1.9%), and 81 (1.5%) patients were in the NTP, DTP, and DNTP groups, respectively. Table 1 shows the baseline characteristics of the patients. Patients in the NTP, DTP and DNTP groups were older (P<0.001), had a higher percentage of male patients (P<0.001), and with a higher incidence of hypertension (P<0.001) compared with the NOP group. The incidence of coronary artery disease in the DTP group (26.2%) was lower than that of the NOP (28.9%), NTP (37.1%), and DNTP (32.1%) groups (P=0.039). Therefore, the percentage of patients who used cardiovascular medications were lower in the DTP group (7.8%) than the other groups (P=0.020). There was no statistical difference among these 4 groups of patients on baseline ECG characteristics, including first-degree AVB (P=0.228), Mobitz type I AVB (P=0.405), left bundle branch block (P=0.501), and right bundle branch block (P=0.366).
Intermediate Pause and Cardiovascular Outcomes
During the follow-up period of 8.8AE1.7 years, a total of 343 (6.5%) patients died. In the 5291 patients, 3061 (57.9%) were hospitalized for any reasons, 1129 (21.3%) were hospitalized for cardiovascular causes, 108 (2.0%) had PPM implantation, 399 (7.5%) developed new-onset AF, 524 (9.9%) had newonset HF, 493 (9.3%) had TIA, and 480 (9.1%) had ischemic stroke episodes. (Tables 2 and 3 ). The above-mentioned cardiovascular event rates were similar among NTP, DTP and DNTP patients, except for PPM implantation rates. PPM implantation rate was higher in the DNTP than that in the NTP (HR, 2.48; P=0.010; Table 2 ) and DTP (HR, 2.64; P=0.041) groups (Table 3) . Ischemic stroke rate was indifferent among the 4 groups of patients (P=ns for any 2 of the 4 groups; Table 2 ). The mortality rate in DTP patients is higher than that of the NOP (HR, 2.26; P=0.001) and NTP (HR, 2.35; P=0.008) patients (Table 2 ). DNTP patients also have a higher mortality rate than that of the NTP (HR, 2.26; P=0.016; Table 2 ) and NOP (HR, 2.04; P=0.008; Table 3 ) patients. Mortality rates were similar between NTP and NOP patients (HR, 1.00; P=0.997) and between DNTP and DTP patients (HR, 1.04; P=0.910; Tables 2 and 3 ). Table 4 .
Intermediate Pause Patterns and Frequencies on Mortality
Mortality rates were similar among different patterns within the NTP (P=0.304), DTP (P=0.710), and DNTP (P=0.440) groups (Table 5) . Kaplan-Meier survival curves showed no differences in mortality rate among different pause patterns within the 3 groups of patients ( Figure 2 ). ISS patients in the DNTP groups had a higher mortality rate than that of ISS patients in the NTP groups (HR, 2.37; P=0.032; Table 6 ). Patients presenting with ISS pattern in the DTP (HR, 1.88; P=0.028) and DNTP (HR, 1.94; P=0.032) groups showed a higher mortality rate than that in the NOP group (Table 6) . Compared with the NOP group, DTP patients with intermediate pause of atrioventricular block pattern also have an increased mortality rate (HR, 4.24; P=0.005; Table 6 ).
Median frequencies of the intermediate pauses were 3, 3, and 23 times/day in the NTP, DTP, and DNTP patients, respectively (Table 7) . Mortality rates were indifferent between high-and low-frequency patients within the NTP (P=0.325), DTP (P=0.221), and DNTP (P=0.484) groups (Table 7) . Kaplan-Meier survival curves showed no difference in mortality rate between the high-and low-pause-frequency patients within the 3 groups of patients (Figure 3 ). Highpause-frequency patients in the DTP (HR, 3.42; P=0.006) and DNTP (HR, 1.72; P=0.023) groups had a higher mortality rate than that in NTP patients with high pause frequency (Table 8) .
Similarly, DTP (HR, 2.64; P=0.001) and DNTP (HR, 2.35; P=0.012) patients with high pause frequency showed increased mortality rate compared with the high-pausefrequency patients in the NOP groups (Table 8 ). Figure 4 shows the percentage of patients in different pause groups according to the causes of death. The leading causes of death in intermediate pause patients are infection and malignancy. DTP and DNTP patients had a higher rate of infectionrelated mortality than that of the NOP patients (DTP versus NOP, P=0.002; DNTP versus NOP, P=0.002; Table 9 ). Similarly, DTP and DNTP patients also had a higher rate of malignancy-related death compared with that of NOP patients (DTP versus NOP, P<0.001; DNTP versus NOP, P=0.004; Table 9 ). Cardiovascular (myocardial infarction, HF, and sudden cardiac death; P=0.084) and other (gastrointestinal bleeding, stroke, chronic obstructive pulmonary diseases, and uremia; P=0.785) causes of mortality rate were similar among these 4 groups of patients.
Percentage and causes of PPM implantation in different pause groups are shown in Figure 5 . Compared with NOP patients, DNTP, DTP, and NTP patients had a higher rate of sick sinus syndrome (DNTP versus NOP, P<0.001; DTP versus NOP, P=0.018; NTP versus NOP, P<0.001) and AVB (DNTP versus NOP, P<0.001; DTP versus NOP, P<0.001; NTP versus NOP, P<0.001) related PPM implantation (Table 10) .
Discussion Main Finding
This study has the following major findings: (1) Intermediate pause occurring at daytime or nighttime increased the risk of pauses solely occurred at nighttime; and (3) in patients with intermediate pauses at daytime, those with sick sinus pattern and high occurrence frequency were at high risk for mortality.
Intermediate Versus Long Pauses on Mortality
Sinus pauses greater than 3 seconds in duration may cause syncope or presyncope, despite some patients only have giddiness or whirling. 1 Current American and European guidelines recommended that permanent cardiac pacing is indicated in patients with pauses ≥3.0 seconds for ventricular activity, either in sinoatrial node dysfunction or abnormality in atrioventricular conduction. However, the current 3-second criterion is an arbitrary clinical observation with a low specificity. 3 Hilgard et al found 47 asymptomatic patients with long (≥3 seconds) pause from 6470 consecutive 24-hour Holter recordings. They reported that no survival benefit was found in these patients receiving pacemaker therapy or not. 9 With this 3-second criteria, Saba et al compared the unpaced long (≥3 seconds) pause patients (n=70) with the no pause (<3 seconds) patients (n=81) and found no difference in survival rate after 2.2 years of follow-up. 10 Similarly, in patients with intermediate (≥2 seconds) pauses, Mazuz et al found no differences in clinical outcomes between paced and unpaced patients. 11 The lack of survival benefit in pacing the long/intermediate pause patients may arise from (1) short observation duration in these studies and (2) AF patients whose criteria for pacing is >5-second pause were not excluded.
In this study excluding patients with AF and followed up to 8 years, we found that intermediate pauses occurring at either daytime or nighttime increased the risk of adverse cardiovascular events, including all/cardiovascular cause of hospitalization, new-onset AF/HF, pacemaker implantation, and TIA. Intermediate pause at daytime was associated with increased mortality rate than that at nighttime. We also found that high pause occurrence frequency was associated with increased mortality rate, suggesting that these intermediate pauses affected patient outcome. To the best of our knowledge, this is the first study to analyze the long-term (>8 years) relationship between intermediate pauses and morbidities. Therefore, intermediate pause occurring at daytime might not be a benign course if patients are followed in a long-term duration. Future studies are warranted to elucidate the clinical significance of this association.
Intermediate Pause at Nighttime Versus Daytime on Cardiovascular Risk
Sinus pauses occurring in the daytime may cause syncope and were considered to be clinically significant. On the other hand, nighttime bradycardia and pause episodes are Table 6 . frequently thought to be benign because they did not produce symptoms. In 50 medical students without cardiovascular diseases receiving 24-hour Holter monitoring, Brodsky found that 28% had sinus pause of >1.75 seconds during sleep, but no adverse events or mortality were reported. 12 Similarly, an observational study also showed that up to 4% to 10% of Figure 3 . Intermediate pause frequency on mortality rates within the NTP (A, cut-off value is 3 times/day), DTP (B, cut-off value is 3 times/day), and DNTP (C, cut-off value is 23 times/day) groups. P values were calculated with the log-rank test in the Kaplan-Meier survival curves. NTP, nighttime pause; DTP, daytime pause; DNTP, daytime plus nighttime pause. The cuff-off value for high vs low frequency was the median values of pause frequency in each group. healthy subjects had sinus pause of ≥2 seconds during sleep without adverse clinical events. 13 These findings suggested that nighttime pause was a benign physiological response because of the suppression of autonomic control during sleep. However, in this study, we found that intermediate pause at nighttime was associated with an increased risk of adverse cardiovascular events, including hospitalization, pacemaker implantation, new-onset AF/HF, and TIA, compared with those without pauses. One possibility for this discrepancy is that most of our enrolled patients are not healthy subjects, having chronic diseases of diabetes mellitus, hypertension, HF, and coronary heart disease. Our data represent a real-world practice results, and most of the patients in clinics did have multiple comorbidities. Further studies are needed to clarify the clinical significance of nighttime intermediate pause.
Intermediate Pauses and New-Onset AF
Sick sinus syndrome is the aging process involving the sinoatrial node and atrial myocardium, leading atrial fibrosis and the development of AF. 14, 15 Bradycardia per se might stimulate atrial ectopic beats and enhance greater dispersion of atrial refractoriness, and both are vital factors for initiating AF. 16 An experimental study also found that interrupted electrical connection between the sinoatrial node and pulmonary veins might facilitate burst firing of the pulmonary veins and occurrence of AF. 17 Therefore, up to 50% of sick sinus syndrome patients with long pauses are accompanied by paroxysmal supraventricular tachycardia, and most of them were AF. 18, 19 Intermediate pause occurring at daytime or nighttime increased the risk of adverse cardiovascular events, and these pauses occurring at daytime, either daytime only or daytime plus nighttime, were correlated to raising mortality rate in this study. Although PPM implantation is not indicated for patients with intermediate pause according to the current guidelines, these patients did have increased risk for future pacemaker implantation observed in this study. 1, 5 Intermediate pause might therefore be a subclinical harbinger for future long pauses that warrant pacemaker implantation, especially in those who developed mild symptoms such as dizziness or 
Study Limitations
Several limitations exist in this study. First, our study was designed retrospectively with variable follow-up periods among patients. Further prospective studies are still necessary to validate our findings. Second, because of the lack of Figure 4 . Mortality rate and causes of deaths in the 4 groups of patients. Causes of cardiovascular deaths included myocardial infarction, heart failure, and sudden cardiac death.
Other causes of death included gastrointestinal bleeding, stroke, chronic obstructive pulmonary diseases, and uremia. DNTP indicates daytime plus nighttime pause; DTP, daytime pause; NOP, no pause; NTP, nighttime pause. Finally, elevated vagal tone during sleep might also contribute to the adverse cardiovascular events in patients with NTP. In this study, we did not record the exact sleep/awake time in the 24-hour monitoring period. We therefore defined the daytime (8:00 AM-8:00 PM) and nighttime (8:00 PM-8:00 AM) regardless patients' sleep/awake status. Previous studies showed that high vagal activity during sleep was associated with elevated heart rate variability, in particular the high- Figure 5 . Causes for permanent pacemaker (PPM) implantation in the 4 groups of patients. Sick sinus syndrome (SSS) included long (>3 seconds in duration) sinus pause, tachybradycardia syndrome, and symptomatic sinus bradycardia. AF indicates atrial fibrillation plus atrioventricular nodal ablation and PPM implantation; AVB, high-degree atrioventricular block; DNTP, daytime plus nighttime pause; DTP, daytime pause; NOP, no pause; NTP, nighttime pause; VT, ventricular tachycardia plus implantable cardioverter-defibrillator implantation. AF indicates atrial fibrillation plus atrioventricular nodal ablation; AVB, (high degree) atrioventricular block; DNTP, daytime plus nighttime pause; DTP, daytime pause; NOP, no pause; NTP, nighttime pause; PPM, permanent pacemaker; SSS, sick sinus syndrome, including long pause, tachybradycardia syndrome, and sinus bradycardia. *VT: ventricular tachycardia plus implantable cardioverter-defibrillator (ICD) implantation.
frequency power of the spectral analysis. 21 Further studies are needed to elucidate how vagal tone reflected by heart rate variability parameters contributes to the cardiovascular risk in patients with NTP.
Conclusion
In patients with intermediate pauses, adverse cardiovascular risk is increased compared with those without intermediate pauses.
Patients with intermediate pauses occurring at daytime are associated with a higher mortality rate than that occurring exclusively at nighttime during long-term follow-up.
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